Engineered CAR T immune cells, mRNA cancer vaccines, and CRISPR-based therapies show potential beyond ultra-rare disorders, necessitating collaboration between scientists and regulators for accessibility.
Challenges like economic feasibility, individualized processes, safety concerns, and regulatory hurdles for personalized therapies can be overcome with collaborative efforts and flexible treatment platforms.
#hyper-personalized-therapies #scientist-collaboration #regulatory-challenges #accessibility #bespoke-treatments
[
add
]
[
|
|
...
]